|
Showing 1 - 8 of
8 matches in All Departments
Extensive research into the molecular mechanisms of cancer has
heralded a new age of targeted therapy. The field of personalized
cancer therapy is now growing rapidly, and the progress being made
will result in significant changes in the treatment algorithms for
cancer patients. Numerous novel targets that are crucial for the
survival of cancer cells can be attacked by small molecules such as
protein tyrosine kinase inhibitors. This book, written by
acknowledged experts, discusses in detail the most recent
developments in targeted cancer therapy using small molecules. A
wide range of small molecules is covered, including, in addition to
tyrosine kinase inhibitors, mTOR, proteasome, and multikinase
inhibitors, among others. For each molecule, aspects such as
chemical structure, mechanism of action, drug targets, drug
interactions, preclinical studies, clinical trials, treatment
applications, and toxicity are discussed.
This book, written by respected experts, discusses in detail the
latest developments in targeted oncology therapy using small
molecules. It covers a wide range of small molecules, including
tyrosine kinase inhibitors, mTOR, MEK, PARP, and multikinase
inhibitors, as well as cell cycle and NTRK interacting agents. For
each molecule, aspects such as the chemical structure, mechanism of
action, drug targets, drug interactions, preclinical studies,
clinical trials, treatment applications, and toxicity are
discussed. Extensive research into the molecular mechanisms of
cancer has heralded a new age of targeted therapy. The field of
personalized cancer therapy is now growing rapidly, and the
advances being made will mean significant changes in the treatment
algorithms for cancer patients. Numerous novel targets that are
crucial for the survival of cancer cells can be attacked by small
molecules such as protein tyrosine kinase inhibitors. This book is
the third edition of Small Molecules in Oncology, but has now been
divided into two volumes, with the other volume focusing
specifically on small molecules in hematology.
This book, written by respected experts, discusses in detail the
latest developments in targeted therapy for hematologic
malignancies using small molecules. It covers a wide range of small
molecules including tyrosine kinase inhibitors, immunomodulatory
drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor
venetoclax, and the proteasome inhibitor carfilzomib. For each
molecule, aspects such as the chemical structure, mechanism of
action, drug targets, drug interactions, preclinical studies,
clinical trials, treatment applications, and toxicity are
discussed. Extensive research into the molecular mechanisms of
cancer has heralded a new age of targeted therapy. The field of
precision cancer therapy is now growing rapidly, and the advances
being made will mean significant changes in the treatment
algorithms for cancer patients. Numerous novel targets that are
crucial for the survival of cancer cells can be attacked by small
molecules such as protein tyrosine kinase inhibitors. An
accompanying volume addresses the use of small molecules in
oncology, and the two volumes together represent the third edition
of the book originally published under the same title.
Extensive research into the molecular mechanisms of cancer has
heralded a new age of targeted therapy. The field of personalized
cancer therapy is now growing rapidly, and the progress being made
will result in significant changes in the treatment algorithms for
cancer patients. Numerous novel targets that are crucial for the
survival of cancer cells can be attacked by small molecules such as
protein tyrosine kinase inhibitors. This book, written by
acknowledged experts, discusses in detail the most recent
developments in targeted cancer therapy using small molecules. A
wide range of small molecules is covered, including, in addition to
tyrosine kinase inhibitors, mTOR, proteasome, and multikinase
inhibitors, among others. For each molecule, aspects such as
chemical structure, mechanism of action, drug targets, drug
interactions, preclinical studies, clinical trials, treatment
applications, and toxicity are discussed.
Extensive research into the molecular mechanisms of cancer disease
has heralded a new age of targeted therapy. In malignant cells, key
proteins that are crucial to tumor growth and survival are now
being targeted directly with rationally designed inhibitors. Apart
from monoclonal antibodies, small molecule therapeutics such as
oncogenic protein kinase inhibitors are attracting a vast amount of
investigational attention. This textbook, written by acknowledged
experts, provides a broad overview of the small molecules currently
used for the treatment of malignant diseases and discusses
interesting novel compounds that are in the process of clinical
development to combat cancer.
This book, written by respected experts, discusses in detail the
latest developments in targeted oncology therapy using small
molecules. It covers a wide range of small molecules, including
tyrosine kinase inhibitors, mTOR, MEK, PARP, and multikinase
inhibitors, as well as cell cycle and NTRK interacting agents. For
each molecule, aspects such as the chemical structure, mechanism of
action, drug targets, drug interactions, preclinical studies,
clinical trials, treatment applications, and toxicity are
discussed. Extensive research into the molecular mechanisms of
cancer has heralded a new age of targeted therapy. The field of
personalized cancer therapy is now growing rapidly, and the
advances being made will mean significant changes in the treatment
algorithms for cancer patients. Numerous novel targets that are
crucial for the survival of cancer cells can be attacked by small
molecules such as protein tyrosine kinase inhibitors. This book is
the third edition of Small Molecules in Oncology, but has now been
divided into two volumes, with the other volume focusing
specifically on small molecules in hematology.
This book, written by respected experts, discusses in detail the
latest developments in targeted therapy for hematologic
malignancies using small molecules. It covers a wide range of small
molecules including tyrosine kinase inhibitors, immunomodulatory
drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor
venetoclax, and the proteasome inhibitor carfilzomib. For each
molecule, aspects such as the chemical structure, mechanism of
action, drug targets, drug interactions, preclinical studies,
clinical trials, treatment applications, and toxicity are
discussed. Extensive research into the molecular mechanisms of
cancer has heralded a new age of targeted therapy. The field of
precision cancer therapy is now growing rapidly, and the advances
being made will mean significant changes in the treatment
algorithms for cancer patients. Numerous novel targets that are
crucial for the survival of cancer cells can be attacked by small
molecules such as protein tyrosine kinase inhibitors. An
accompanying volume addresses the use of small molecules in
oncology, and the two volumes together represent the third edition
of the book originally published under the same title.
|
|